Replies to post #117510 on Biotech Values

[mcbio]

I find it a bit premature that INHX now sports a $300M market cap. They are clearly riding the coattails of VRUS and their success with HCV nukes, notwithstanding the fact that VRUS has multiple nukes that are much, much further along in the clinic with data in hand that will probably be difficult for INX-189 to replicate. Also, after the issues with their shingles candidate, I think this HCV nuke is pretty much all they have left. Not a bet I'd want to take on at a $300M market cap although I guess stranger things have happened.